Regulation of hepatic cholesterol metabolism in CETP+/-/ LDLr+/- mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 12, 2006, Pages 1209-1215

  Harada, Lila M ^a   Carrilho, Alexandre J F ^b   Oliveira, Helena C F ^c   Nakandakare, Edna R ^a   Quintão, Eder C R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STATE UNIVERSITY OF LONDRINA   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cholesteryl ester transfer protein; Cholestyramine; Lovastatin; Low density lipoprotein receptor; Transgenic mice

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESTYRAMINE; CYTOCHROME P450; CYTOCHROME P450 27; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MEVINOLIN; SCAVENGER RECEPTOR BI; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG ACTIVITY; LIVER MICROSOME METABOLISM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, DIETARY; CHOLESTYRAMINE; LIPID METABOLISM; LIVER; LOVASTATIN; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; RECEPTORS, LDL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIGLYCERIDES;

EID: 33845547155     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04512.x     Document Type: Article

References (43)

1. Bruce C, Chouinard Jr RA, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu. Rev. Nutr. 1998; 18: 297-330.
2. Drayna D, Jarnagin AS, McLean J et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987; 327: 632-4.
3. Jiang XC, Moulin P, Quinet E et al. Mammalian, adipose tissue and muscle are major sources of lipid transfer protein mRNA. J. Biol. Chem. 1991; 266: 4631-9.
4. Oliveira HCF, Chouinard RA, Agellon LB et al. Human cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive responsive elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5′ distal sequences. J. Biol. Chem. 1996; 271: 31 831-8.
5. Quinet EM, Agellon LB, Kroon PA et al. Atherogenic diet increases cholesteryl ester transfer protein messenger RNA levels in rabbit liver. J. Clin. Invest. 1990; 85: 357-63.
6. McPherson R, Mann CJ, Tall AR et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler. Thromb. 1991; 11: 797-804.
7. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364: 73-5.
8. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. J. Clin. Invest. 1992; 90: 1290-5.
9. Chouinard RA, Luo Y, Osborne TF, Walsh A, Tall AR. Sterol regulatory element binding protein-1 activates the cholesteryl ester transfer protein gene in vivo but is not required for sterol up-regulation of gene expression. J. Biol. Chem. 1998; 273: 22 409-14.
10. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 2000; 105: 513-20.
11. Masucci-Magoulas L, Plump A, Jiang XC, Walsh A, Breslow JL, Tall AR. Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein E and low density lipoprotein receptor gene knockout mice. J. Clin. Invest. 1996; 97: 154-61.
12. Carrilho AJ, Medina WL, Nakandakare ER, Quintão ECR. Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. Clin. Pharmacol. Ther. 1997; 62: 82-8.
13. Korhonen T, Hannuksela ML, Seppanen S, Kervinen K, Kesaniemi YA, Savolainen MJ. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment. Eur. J. Clin. Pharmacol. 1999; 54: 903-10.
14. Ahnadi CE, Berthezene F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 1993; 99: 219-28.
15. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 189-97.
16. McPherson R. Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. Can. J. Clin. Pharmacol. 1999; 6: 85-90.
17. Bisgaier CL, Essenburg AD, Auerbach BJ et al. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J. Lipid Res. 1997; 38: 2502-15.
18. Bradford RH, Shear CL, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. 1991; 151: 43-9.
19. Chao Y, Chen JS, Hunt VM et al. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Eur. J. Clin. Pharmacol. 1991 (Suppl. 1); 40: S11-14.
20. Reihner E, Angelin B, Rudling M, Ewerth S, Bjorkhem I, Einarson K. Regulation of hepatic cholesterol metabolism in human. Stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients. J. Lipid Res. 1990; 31: 2219-26.
21. Carr TP, Andersen CJ, Rudel LL. Enzymatic determination of triacylglycerol, free cholesterol, and total cholesterol in tissue lipid extracts. Clin. Biochem. 1993; 26: 39-42.
22. Lowry OH, Rosebrough NJ, Jarr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
23. Auboeuf D, Vidal H. The use of the reverse transcription-competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples. Anal. Biochem. 1997; 245: 131-48.
24. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c mRNA for sterol regulatory lelemt binding protein-1 in human and mouse organs and cultured cells. J. Clin. Invest. 1997; 99: 838-45.
25. Out R, Hoekstra M, de Jager SC et al. Adenovirus-mediated hepatic overexpression of scavenger receptor BI accelerates chylomicron metabolism in C57BL/6J mice. J. Lipid Res. 2005; 46: 1172-81.
26. Espirito Santo SMS, Patrick CN, Rensen PCN et al. Triacylglycerolrich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. J. Lipid Res. 2005; 46: 1097-102.
27. Miyake JH, Duong-Polk XT, Taylor JM et al. Transgenic expression of cholesterol-7a-hydroxylase prevents atherosclerosis in C57BL7/6J mice. Arterioscler. Thromb. Vasc. Biol. 2000; 22: 121-6.
28. Einarsson K, Akerlund JE, Bjorkem I. The pool of free cholesterol is not of major importance for regulation of the cholesterol 7α-hydroxylase activity in rat liver microsomes. J. Lipid Res. 1987; 28: 253-6.
29. Krause BR, Newton RS. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: Triacylglycerol-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 1995; 117: 237-44.
30. Ness GC, Chambers CM, Lopes D. Atorvastatin action involves diminidhed recovery of hepatic HMG-CoA reductase activity. J. Lipid Res. 1998; 39: 75-84.
31. Jiang XC, Masucci-Magoulas L, Mar J et al. Down regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. J. Biol. Chem. 1993; 268: 27 406-12.
32. Harada IM, Amigo L, Cazita PM et al. CETP expression enhances liver HDL-cholesterol ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis 2006; 24 June [Epub ahead of print].
33. Chin DJ, Luskey KL, Anderson RG, Faust JR, Goldstein JL, Brown MS. Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Proc. Natl Acad. Sci. USA 1982; 79: 1185-9.
34. Bilhartz LE, Spady DK, Dietschy JM. Inappropriate hepatic cholesterol synthesis expands the cellular pool of sterol available for recruitment by bile acids in the rat. J. Clin. Invest. 1989; 84: 1181-7.
35. Spady DK, Cuthbert JA. Regulation of hepatic sterol metabolism in the rat. Parallel regulation of activity and mRNA of 7α-hydroxylase but not 3-hydroxy-3-methylglutaryl-coenzyme A reductase or low density lipoprotein receptor. J. Biol. Chem. 1992; 267: 6684-91.
36. Dueland S, Drisko J, Graf L, Machleder D, Lusis AJ, Davis RA. Effect of dietary cholesterol and taurocholate on cholesterol 7α-hydroxylase and hepatic LDL receptor in inbred mice. J. Lipid Res. 1993; 34: 923-31.
37. Chiang JYL, Kimmel R, Weinberger C, Stroup D. Farnesoid X receptor responds to bile acids and represses cholesterol 7α-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. 2000; 275: 10 918-24.
38. Gupta S, Pandak WM, Hylemon PB. LXRa is the dominant regulator of CYP7A1 transcription. Biochem. Biophys. Res. Commun. 2002; 293: 338-43.
39. Kotake H, Sekikawa A, Tokita Y, Ishigaki Y, Oikawa S. Effect of HMG-CoA reductase inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia: Comparison among CETP/TaqIB genotype subgroups. J. Atheroscler. Thromb. 2002; 9: 207-12.
40. Carlquist JF, Muhlestein JB, Horne JB et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am. Heart J. 2003; 146: 1007-14.
41. Klerkk AH, de Grooth GJ, Zwinderman AH, Jukema JW, Kuinenhonen JA, Kastelein JJ. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease. Eur. J. Clin. Invest. 2004; 34: 21-8.
42. de Grooth GJ, Smilde TJ, Van Wissen S et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004; 173: 261-7.
43. Doggrell SA. Inhibitors of cholesteryl ester transfer protein: A new approach to coronary artery disease. Expert Opin. Invest. Drugs 2006; 15: 99-106.